Chronic disease comorbidity in patients with oral leukoplakia: A matched case-control study

Lance W Giudice, Emrik A Graff, Yasmita Haripersad, Agnieszka M Frydrych, Richard Parsons, Omar Kujan, Camile S Farah

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

OBJECTIVE: The purpose of this study was to investigate the presence of chronic diseases in patients with oral leukoplakia (OL) compared to controls matched for age group, gender, smoking and alcohol use.

SUBJECTS AND METHODS: This case-control study examined the general demographics, medical and social histories of 105 OL cases and 391 controls matched for age group, gender, tobacco and alcohol use. All OL cases were diagnosed based on both clinical and histopathological findings.

RESULTS: Chronic diseases were significantly associated with OL, namely dyslipidaemia (p<0.0001), musculoskeletal diseases (p=0.0101) and asthma (p=0.0052). The use of ACE inhibitors (p=0.0177), opioid analgesics (p=0.0300), anticoagulants (p=0.0055) and statins (p=0.0010) was significantly associated with OL. Dyslipidaemia (p<0.0001; odds ratio (95%CI): 6.4 (3.5-11.6)) and asthma (p=0.0110; odds ratio (95% CI): 2.2 (1.2 - 4.0)) were identified as independent predictors of OL in multivariate analysis, both of which were significantly more common amongst cases than controls.

CONCLUSIONS: Results from this first Australian study suggest that dyslipidaemia and asthma may constitute independent predictors for the presence of OL. However longitudinal studies are needed to ascertain the temporal relationship between OL and chronic disease comorbidity and the mechanisms underlying these associations.

Original languageEnglish
Pages (from-to)894-902
Number of pages9
JournalOral Diseases
Volume26
Issue number5
Early online date27 Feb 2020
DOIs
Publication statusPublished - 1 Jul 2020

Fingerprint

Dive into the research topics of 'Chronic disease comorbidity in patients with oral leukoplakia: A matched case-control study'. Together they form a unique fingerprint.

Cite this